




Lehigh Valley Hospital 3€ Muhlenberg Hospital Center 
• • • • • • • • • • • • • • • 
June, 1998 3€ Volume 10, Number 6 
In This Issue ... 
Year 2000 (Y2K) Compliant Project 
Pages 2 & 3 







Papers, Publications and Presentations 
Pages 5 & 6 
Upcoming Seminars, Conferences and 
Meetings 
Pages 6 & 7 
News from Muhlenberg Hospital Center 
Page 10 
Therapeutics at a Glance 
Pages 11-15 






I think this month I'll start with the pure 
and simple before taking on the rare and 
never parts! 
A new initiative is underway here at 
Lehigh Valley Hospital. Led by Joanne 
Lynn, MD, and Joe Vincent, MD, A 
Center for Improved Care of the Dying is 
attempting to develop an educational 
process for health care providers and 
coordinate a team approach for all 
caregivers who interact with those at the 
end of life. As more of us become 
involved in the patient and family 
dynamics of the dying, we will help 
define end of life care as more than just 
pain control. As a staff, I think we all 
should applaud Drs. Lynn and Vincent 
for their efforts with this project. For 
anyone interested in participating, I 
would ask that you contact Joe or Ms. 
Gale Brunst, the Critical Care secretary, 
at 402-8450. 
On the political front, we won some and 
lost some. The contest between Pat 
Toomey and Roy Afflerbach for the 15th 
Congressional District seat in the fall will 
be an interesting and important one. I 
continue to urge your participation in the 
political process so that the voices of 
physicians will be heard in both 
Harrisburg and Washington. 
{Continued on Page 2) 
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That voice was heard recently in one very important area. 
Due to both a grassroots outcry and effective lobbying by 
organized medicine, the new Evaluation/Management 
Guidelines, due to become effective July 1, 1998, have 
been tabled pending further consideration. The concerns 
of physicians that these guidelines were onerous and 
punitive garnered enough support to detour yet another 
governmental juggernaut. As time consuming as it may 
be, we owe it to our patients and ourselves to be a 
formidable, organized force. James R. Reagan, MD, 
Chair, Pennsylvania Medical Society, will be our guest at 
our next Quarterly Medical Staff meeting on June 8 to 
discuss the value of organized medicine. 
The Lehigh Valley Hospital/Muhlenberg Hospital Center 
Medical Staff Transition Team continues to meet every 
other week. The consensus of this group is that four 
seats dedicated to representatives from the Muhlenberg 
Hospital Center campus should be added to the existing 
Medical Executive Committee. This structure would 
preserve both Muhlenberg Hospital Center cultural 
representation and an at-large member majority of this 
very important committee. 
Now for the least pure and simple topic of my term: the 
exclusive contract between our Division of Cardiac 
Surgery and Lehigh Valley Hospital. As everyone knows, 
the Lehigh Valley Hospital Board of Trustees, at its May 
meeting, passed a resolution to require that our cardiac 
surgeons enter into a mutually exclusive arrangement 
with Lehigh Valley Hospital. This decision generated 
widespread unrest among the medical staff precipitating 
a Medical Staff/Administrative exchange session. During 
this meeting, the same concerns represented at the 
Board of Trustees meeting by the physician members 
were echoed by the vast majority of attendees. The 
physician board members in attendance will convey not 
only the content of, but also the visceral reaction 
generated by, this discussion during the June Board of 
Trustees meeting. In addition, a special meeting of the 
Medical Staff, dedicated to this topic, will take place on 
Thursday, June 4, 1998, at 5:45p.m., in the hospital's 
Auditorium, prior to our Quarterly General Medical Staff 
Meeting on Monday, June 8, at 5:45p.m. 
If only we did not "live in such interesting times" .... 
~ 
Robert X. Murphy, Jr., MD 
President, Medical Staff 
For Your Calendar 
+ A SPECIAL meeting of the General Medical 
Staff will be held on Thursday, June 4, 
beginning at 5:45 p.m., in the hospital's 
Auditorium at Cedar Crest & 1-78. Exclusive 
contracts will be the topic of discussion. 
+ A meeting of the General Medical Staff will be 
held on Monday, June 8, beginning at 5:45 
p.m., in the hospital's Auditorium at Cedar 
Crest & 1-78. All members of the Medical Staff 
are encouraged to attend. 
+ There will be a General Membership meeting of 
the Greater Lehigh Valley Independent Practice 
Association, Inc., on Monday, June 22, 
beginning at 6 p.m., in the Auditorium at Cedar 
Crest & 1-78. Physicians attending this meeting 
will receive credit toward the Incentive Plan. 
Year 2000 (Y2K) Compliant Project 
An effort is underway at Lehigh Valley Hospital and 
Health Network to ensure a smooth transition at the end 
of the century when processor dates rollover from 
December 31, 1999 to January 1, 2000. Date problems 
may arise in a wide selection of products including 
computer hardware and software, systems with 
embedded chips for maintenance tracking, and in some 
bio-med equipment. Systems and equipment that will 
smoothly handle this date rollover are said to be Year 
2000 Compliant. Systems and equipment not Year 
2000 compliant may simply stop-working on Januafi 
1, 2000 or may continue to function but will process 
dates incorrectly. 
(Continued on Page 3) 
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, he entire Year 2000 Project is directed by Harry Lukens, 
Chief Information Officer, and Fred Heller, Director, 
Internal Audit. AI Roeder is the Project Manager and is 
assisted by a group of Information Services analysts and 
coordinators from all areas of the hospital including 
Biomedical Engineering, Patient Care, Medical Records, 
Health Services Division, Supplier Services, Security, 
Facilities and Construction, Finance, and Engineering. 
There are about 250 computer systems at L VH, plus 
another 200 in-house databases using multiple versions 
of software packages such as Powerpoint, Paradox, 
Access, Lotus, Foxpro, and Excel. A process is currently 
in place to identify systems at the Muhlenberg Hospital 
Center. 
Enterprise-wide risk assessments have identified 66 
computer systems as mission critical to the operation of 
the hospital. Workplans, test environments, and 
procedures for testing have been developed for· each of 
the mission critical systems, and most of the bio-med 
( ievices. 
Embedded systems may present us with the greatest 
challenge. Tiny microprocessor chips containing date 
and maintenance data exist in a variety of equipment and 
devices, from non-medical equipment (fax machines and 
security devices), to life supporting equipment 
(pacemakers and defibrillators). There is no guarantee 
that items from the same vendor and with the same 
model number are Year 2000 compliant, because the 
microprocessor chips come from different vendors. 
At this time, most of the products that will be affected 
have been identified. Letters have been sent to vendors 
requesting information about the Year 2000 compliancy 
of their products. Many vendors promise to have 
solutions "sometime during 1999," which means 1999 will 
be a very busy year for Information Services. 
To keep the Year 2000 problem at LVHHN from 
increasing in scope, vendors who supply products or 
systems are now required to guarantee every product 
( ,urchased is compliant. 
Information Services recently tested the PHAMIS hospital 
information system. Several compliance problems have 
been identified. Commitments have been made by 
PHAMIS to fix these problems within the next 180 days. 
Information Services is available to answer any general 
questions you have about this problem, or about specific 
hospital vendors, however, they are not very 
knowledgeable about the office practice vendors. They 
will be happy to share whatever information they have, 
including sample letters to the vendors. 
Information Services will continue to provide information 
about this effort on an e-mail bulletin board, as well as 
updates in the hospital's various communication pieces. 
The bulletin board will include a list of vendors used by 
the hospital, as well as contact names and addresses. 
If you want to know more about the Year 2000 problem, 
the following is a short list of web sites with further 
information : 
• Year 2000 - Countdown to year 2000 and links to 
many related articles 
http://www. year2000 .com 
• Rx2000 Solutions Institute - Links to Hospital 
related Y2K services 
http://www.rx2000.org 
• Microsoft Year 2000 Resource Center 
http://www .microsoft.com/year2000/ 
• Year 2000 ... Are You Ready?- Lehigh 
University's Y2K site 
http://www.lehigh.edu/y2k/y2kdetail.html 
If you have any questions regarding the Year 2000 
Compliance project, please contact AI Roeder in 
Information Services at 402-1480. 
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Vascular Laboratory Receives 
Reaccreditation 
Each year, two million people in the United States alone 
develop deep vein thrombosis-blood clots in the veins. 
This affliction becomes life threatening for 500,000 of 
those people when the blood clot breaks loose and 
travels to their lungs. With early detection through the 
use of non-invasive vascular testing, this disease can be 
prevented. 
Although life threatening if undetected, early detection of 
these vascular diseases is possible through the use of 
non-invasive vascular testing techniques performed 
within vascular laboratories. 
The Vascular Laboratory at Lehigh Valley Hospital was 
recently reaccredited in four areas by the lntersocietal 
Commission for the Accreditation of Vascular 
Laboratories {ICAVL). Those areas include: peripheral 
arterial testing, peripheral venous testing, intracranial 
cerebrovascular testing, and extracranial cerebrovascular 
testing. 
Initially accredited in 1994, L VH's Vascular Laboratory 
was among the first 965 vascular laboratories in the 
United States, Canada, and Puerto Rico to be granted 
accreditation by ICAVL. 
The ICAVL, a non-profit organization established with the 
support of 10 medical societies, provides a mechanism 
for accrediting facilities which perform comprehensive 
testing for vascular disease with non-invasive testing 
modalities. Ten sponsoring societies represent the 
medical specialties of radiology, ultrasonography, 
vascular surgery, neurology, cardiology, neurosurgery 
and internal medicine. 
Accreditation status signifies that the facility has been 
reviewed by an independent agency which recognizes 
the laboratory's commitment of quality testing for 
diagnosis of vascular disease. Participation in the 
accreditation process is voluntary and demonstrates the 
laboratory's concern for high quality patient care and 
attention to quality assurance. 
Library News ( 
OVID Training 
To schedule a one-on-one OVID (MEDLINE) training 
session, call Barbara lobst in the Health Sciences Library 
at 402-8408. 
New Books· Cedar Crest & 1·78 
The Dartmouth Atlas of Health Care 
Author: Dartmouth Medical School 
Call No. WA 900 AA1 D226 
Cumulative Trauma Disorders 
Author: A. Cassvan, et al. 
Call No. WE 175 C9709 
Concise Guide to Psychiatry, 2nd ed. 
Author: J. Spar 
Call No. WT 39 S736c 
Clinical Hypertension 
Author: N. Kaplan 
Call No. WG 340 K17c 
New Books· 17th & Chew 
Medical Pharmacology at a Glance, 3rd ed. 
Author: M .J. Neal 
Call No. QV 38 N342m 
Multidisciplinary Atlas of Breast Surgery 
Author: D. Kinne 
Call No. WP 17 M961 
Critical Care of the Surgical Newborn 
Author: D. Nakayama, et al. 
Call No. WS 421 C934 
Acute Care Psychiatry: Diagnosis and Treatment 
Author: L. Sederer, et al. 
Call No. WM 141 A189 
( 
( 
Medical Staff Progress Notes June, 1998 X Volume 10, Number 6 Page5 
Congratulations! 
Richard S. MacKenzie, MD, Vice Chairperson, 
Department of Emergency Medicine, was recently 
appointed Chair of the Public Relations Committee of the 
American College of Emergency Physicians, a national 
association of over 19,000 physicians. 
Papers, Publications and 
Presentations 
Wayne E. Dubov, MD, Division of Physical 
Medicine/Rehabilitation, was a guest speaker at an 
Impairment Rating seminar sponsored by Tallman, 
Hudders, and Sorrentino, held at Lehigh University on 
May 6. His topic was "Impairment Rating Evaluations--
General Approach and Historical Background." Dr. 
Dubov also presented "Peripheral Nerve Injuries in the 
Trauma Population" at the Pennsylvania National 
Association of Rehabilitation Professionals in the Private 
Sector held on May 14 in Hershey. 
( .n addition, Dr. Dubov was taped for two television 
appearances on "Challenges" which is broadcast on 
Channel69. The first appearance, "Future of Health 
Care," aired on May 18 at 8:30p.m. The second, "Seat 
Belt and Helmet Legislation-- Choice to Choose," will air 
on Channel 69 on June 15 at 8:30 p.m. 
John P. Fitzgibbons, MD, Chairperson, Department of 
Medicine, chaired a symposium on "Resident Scholarly 
Activity" at the Association of Program Directors in 
Internal Medicine meeting held March 31 in San Diego 
~[ I 
Mark A. Gittleman, MD, Division of General Surgery, 
presented an all day seminar on "Stereotactic Breast 
Biopsy" at the Summit Surgical Center in Voorhees, NJ. 
In addition, Dr. Gittleman was invited to deliver a lecture 
on "Breast Ultrasound and the Surgeon" at the Michigan 
Chapter of the American College of Surgeons annual 
meeting held May 8 and 9 in Lansing, Mich. 
( 0 eter A. Keblish, MD, Chief, Division of Orthopedic 
.:Surgery, was an invited guest speaker at the Japanese 
Orthopaedic Society meeting in Takashima, Japan, in 
April. The meeting was the ?1st annual Japanese 
Orthopaedic Association/International Society which 
consists of over 10,000 members. Dr. Keblish spoke on 
issues of technique, approaches, and results of total 
knee arthroplasty and was also the moderator in the 
sessions that dealt with practical and theoretical aspects 
of knee replacement. 
Colin P. Kopes-Kerr, MD, Department of Family 
Practice, was a guest speaker at the Annual Family 
Practice Review Course sponsored by the University of 
Tennessee in Memphis, Tenn. He gave two presenta-
tions- The Ten Most Under Used Prescriptions in the 
U.S. (aspirin, beta-blockers post-MI, menopausal 
estrogens, antidepressants, anti-inflammatory 
medications for asthma, peripheral alpha-blockers for 
hypertension, ACE-inhibitors for hypertension, CHF, and 
diabetes, pneumococcal vaccine, fiber, and exercise}; 
and Management of the Complications of the 
Common Cold: What the Literature Tells Us. 
Vincent ~· Lucente, MD, Chief, Division of Gynecology, 
and Sect1on of Pelvic Reconstructive Surgery, was a 
speaker at the Annual Clinical Meeting of the American 
C?llege of O~stet~~cians and Gynecologists held in May. 
H1s talk was t1tled Laparoscopic Reconstructive Pelvic 
Surgery-- Its Current and Evolving Role." 
William L. .Miller, MD, Vice Chairperson and Residency 
Program Director, Department of Family Practice, had a 
number of speaking engagements during the past few 
months. In March, Dr. Miller was an invited speaker at 
the Minnesota Research Network in St. Paul, Minn. His 
keynote speech was "Qualitative Research - Evidence 
that Really Matters." He also presented a one-hour 
workshop on "Doing Qualitative Research." 
In early April, Dr. Miller was an invited speaker at the 
Pennsylvania Spring Family Medicine Conference held in 
Philadelphia, Pa., which was sponsored by Pennsylvania 
Famil~ Pra~tice. Dr. Miller co-presented "Turning 
Questions mto Answers: Various Research Methods." 
He also gave a 30-minute presentation to medical 
students on "Choosing a Residency." 
In late April, Dr. Miller presented "Creating Culture in 
Residency Training Programs" at the Society of Teachers 
of Family Medicine Annual Spring Conference which was 
held in Chicago, Ill. 
(Continued on Page 6) 
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Lester Rosen, MD, Associate Chief, Division of Colon 
and Rectal Surgery, was an invited speaker at the 
American Society of Colon and Rectal Surgeons Annual 
Meeting, held May 2 to 7, in San Antonio, Texas. He 
presented the forum, "Survival Skills for the Clinical and 
Academic Surgeon," which covered the necessary 
framework for outcome analysis and its transition into a 
performance report card, useful for quality management, 
research and education. Additionally, he was one of the 
speakers in "Meet the Professor'' forums, dealing with 
Quality of Care Indicators. 
Alexander M. Rosenau, DO, Associate Vice 
Chair/Practice Management, Department of Emergency 
Medicine, joined the University of Massachusetts/ 
American College of Emergency Physicians emergency 
medicine mission to Israel as a visiting professor from 
March 9 to 12. He lectured and participated in panel 
discussions at the conference which occurred upon the 
first anniversary of Israel's recognition of Emergency 
Medicine as a distinct specialty in Israel. This conference 
was held in concert with the Fifth Annual Scientific 
Assembly of the Israeli Association for Emergency 
Medicine. Physicians from Australia, Canada, Israel, 
Jordan, and the United States participated. Last year, 
MichaelS. Weinstock, MD, Chairperson, Department of 
Emergency Medicine, participated in this program on the 
day of official recognition of the specialty. 
MichaelS. Weinstock, MD, Chairperson, Department of 
Emergency Medicine, was recently a Visiting Professor at 
both Bowman Gray School of Medicine and at Geisinger 
Hospital where he presented "An Environmental 
Assessment of Emergency Medicine in T oday's Health 
Care Environment" as well as clinical topics in emergency 
medicine. 
Upcoming Seminars, Conferences 
and Meetings 
08/GYN Resident Research Day 
The Department of Obstetrics and Gynecology will hold 
the Sixth Annual Joseph A. Miller, MD Resident 
Research Day on Friday, June 5, beginning at 7:30a.m., 
in the hospital's Auditorium at 17th & Chew. ( 
Keynote speakers William Droegemueller, MD, University 
of North Carolina, and Paula Hillard, MD, University of 
Cincinnati, will present "Burnout in OB/GYN" and 
"Pediatric Gynecology." In addition, eight 08/GYN 
residents will present their projects, representing the 
culmination of this year's research efforts. 
To register for 08/GYN Resident Research Day, please 
call Bonnie Schoenberger at 402-1210. 
Medical Grand Rounds 
Medical Grand Rounds are held every Tuesday from 
Noon to 1 p.m., in the hospital's Auditorium at Cedar 
Crest & 1-78. 
Topics to be discussed in June include: 
• June 2- Kidney Transplantation- What the Internist 
Needs to Know 
• June 9 - When Arms Become Legs ( 
There will be no Medical Grand Rounds during the 
summer; however, they will resume on Tuesday, 
September 8. Have a Wonderful Summer! 
For more information, please contact Evalene Patten in 
the Department of Medicine at 402-1649. 
Department of Pediatrics 
Department of Pediatrics conferences are held on 
Fridays at Noon in the hospital's Auditorium at 17th & 
Chew. 
Topics to be discussed in June include: 
• June 12 - Preoperative Evaluation of Children 
• June 26 - Topic to be announced 
Noon conferences will resume in September. 
For more information, please contact Kelli Ripperger in ( 
the Department of Pediatrics at 402-2540. 
(Continued on Page 7) 
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Customer Service Special Event 
On Monday, July 13, Quint Studer, CEO of Baptist 
Hospital in Pensacola, Fla., will share his strategies with 
hospital staff and physicians as to how he used the 
Press, Ganey survey to improve customer service at 
Holy Cross Hospital in Chicago while he was employed 
there. Their scores went from the 14th percentile to the 
98th percentile in one year. Using these strategies, Mr. 
Studer is accomplishing similar results at Baptist 
Hospital. 
The sessions will be as follows: 
9 a.m. 
to 11 a.m. 
11:30 a.m. 
to 12:30 p.m. 
2:30p.m. 
to 3:30p.m. 
Department Heads and Physicians 
Auditorium, L VH, Cedar Crest & 1-78 
Hospital staff and Physicians who 
couldn't make the first session 
Auditorium, LVH, Cedar Crest & 1-78 
First Floor Conference Room 
Muhlenberg Hospital Center 
If you have any questions, please contact Nancy 
Stevens, Patient Representative, at 402-8222. 
How Much Does It Cost to Stay in the Hospital? 
Beginning with this issue of Medical Staff Progress Notes, 
information will be provided to inform members of the 
Medical Staff of the costs associated with the care of their 
patients at Lehigh Valley Hospital. 
Listed below are the costs, per day, of the various levels of 
care. These nursing unit costs include staff, supplies, and 
unit management; they do not include fixed expenses or 
ancillary costs. 
• Intensive bed 
• Intermediate bed- TTU, PCCU, TOHU 
• Med/Surg bed 






To clear up a rumor that has been circulating regarding 
reimbursement for sigmoidoscopies and colonoscopies, the 
following information has been issued by Patient Accounting. 
At the present time, most payers will reimburse for 
sigmoidoscopies and colonoscopies that are performed in the 
hospital setting, with the following exception. Independence 
Blue Cross, which includes Personal Choice, Keystone 
Health Plan East, and Blue Choice, will not pay for 
sigmoidoscopies done in a hospital setting, including the 
clinic. Sigmoidoscopies are only reimbursed if done in the 
physician's office. Patients who have an Independence Blue 
Cross plan will be billed for the hospital service if the 
sigmoidoscopy is done at the hospital. The physician 
reimbursement will not be affected. 
Please inform your patients that if they are covered by an 
Independence Blue Cross plan, they will receive a bill from 
the hospital if they choose to use the hospital setting. 
If you have any questions, please contact Sandra Colon, 
Director of Patient Accounting, at 402-9461. 
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Who's New at LVH 
The Who's New section of Medical Staff Progress Notes 
contains an update of new appointments, address 
changes, status changes, etc., for members of the 
Medical Staff of Lehigh Valley Hospital. 
Medical Staff 
New Appointments 
Serena A. Jung, MD 
Allentown Anesthesia Associates Inc. 
1251 S. Cedar Crest Blvd. 
Suite 212C 
Allentown, PA 18103-6243 
(610) 402-8810 
Fax: (610) 402-8008 
Department of Anesthesiology 
Provisional Active 
John G. Pearce, MD 
Medical Imaging of LV, PC 
Breast Health Services 
1240 S. Cedar Crest Blvd. 
Suite 203 
Allentown, PA 18103-6218 
(61 0) 402-0690 
Fax: (610) 402-0695 
Leave of Absence 
Richard M. Herman, MD 
Department of Surgery 
Division of Otolaryngology 
From 3/1/98 to 2/28/2000 
Change of Practice 
Eric J. Bodish, MD 
From L VPG-Emergency Medicine 
to McGarry & Bodish 
Allentown Medical Center 
401 N. 17th Street · 
Suite 105 
Allentown, PA 181 04-5088 
(61 0) 432-2013 
Fax: (610) 432-6559 
Address Changes 
Harold J. Goldfarb, MD 
Liberty Square Medical Center 
501 N. 17th Street 
Suite 111 
Allentown, PA 18104 
(61 0) 776-1935 
Howard A. Silverman, MD 
Park Professional Building 
2200 Hamilton Street 
Suite 103 
Allentown, PA 18104-6329 
Status Changes 
Eric J. Bodish, MD 
From Department of Emergency Medicine 
Division of Emergency Medicine 
to Department of Medicine 
Division of General Internal Medicine 
Provisional Active 
Malcolm L. Cowen, MD 
Department of Pathology 
Division of Forensic Pathology 
From Active to Emeritus Active 
Bruce A. Frankenfield, MD 
Department of Medicine 
Division of General Internal Medicine 
From Associate to Emeritus Associate 
Donald B. Kopenhaver, MD 
Department of Obstetrics and Gynecology 
Division of Primary Obstetrics and Gynecology 
From Affiliate to Honorary 
Joseph N. Nader, MD 
Department of Medicine 
Division of Cardiology 
From Active to Emeritus Active 
Raymond A. Rachman, MD 
Department of Pathology 
Division of Clinical & Anatomic Pathology 
From Active to Emeritus Active 
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( John S. Wheeler, MD 
Department of Pediatrics 
Division of General Pediatrics 
From Associate to Emeritus Affiliate 
Appointments to Leadership Positions 
George A. Arangio, MD 
Associate Chief 
Division of Orthopedic Surgery 
Weldon E. Chafe, MD 
Chief 
Section of Gynecologic Oncology 
Stephen C. Matchett, MD 
Medical Director 
Special Care Unit 
Resignations 
( "t:, Michael Adams, MD 
(Kutztown Primary Care Associates) 
Department of Family Practice 
( 
C. Daniel Hendrickson, MD 
(L VPG-Medicine) 
Department of Medicine 
Division of General Internal Medicine/Ambulatory Care 
Ellen M. Joyce, MD 
(College Heights OBGYN Associates, PC) 
Department of Obstetrics and Gynecology 
Division of Primary Obstetrics and Gynecology 
Allied Health Professionals 
Appointments 




(Coordinated Health Systems - Brett Godbout, MD) 




(Allentown Anesthesia Associates Inc. - Alphonse 
Maffeo, MD) 




(Candia, Kovacs & Lakata, PC - Robert Kovacs, MD) 




(Allentown Anesthesia Associates Inc. - Alphonse A. 
Maffeo, MD) 




(Oncology Specialists of Lehigh Valley- Gregory R. 
Harper, MD) 
Resignations 




(L VPG-Emergency Medicine - Michael Weinstock, MD) 




(L VPG-Pediatrics - Charles Smith, MD) 




Glucose Monitoring System 
Implemented at MHC 
Effective May 4, the Sure Step Pro (glucose monitoring 
system) was implemented at Muhlenberg Hospital 
Center on the following units- CVU, ICCU, 3 South, and 
4 South. A physician's order is required to use the Sure 
Step Prometer to obtain a capillary blood glucose 
measurement (except in an emergency) to help rule out 
hypoglycemia or hyperglycemia. The order must specify 
the timing and frequency of performing the blood glucose 
tests and state Blood Surgars per glucose meters. 
Insulin infusion protocol can also be instituted with a 
physician's order. 
The Bedside Glucose Monitoring Flow Sheet will be used 
by nursing to document monitor readings, serum glucose 
comparisons, and continuous insulin infusion information. 
Intermittent insulin administrations will be documented on 
the medication record. 
The flow sheet will be kept at the patient's bedside and 
placed on the chart in the graphics section when 
completed. 
The institution of the glucose meter is one of the first 
steps taken to standardize practice at Lehigh Valley 
Hospital and Muhlenberg Hospital Center. 
If you have any questions regarding this issue, please 
contact Sharon Rabuck, RN, Clinical Instructor, at 
861-2413. 
For Your Calendar ( 
The Annual Meeting of the Muhlenberg Hospital Center 
Medical Staff is scheduled for Monday, June 15, 
beginning at 6:30 p.m., in the hospital's cafeteria. Harry 
Lukens, Senior Vice President and CIO, will be present to 
speak to the Medical Staff about Information Services at 








THERAPEUTICS AT A GLANCE 
The following actions were taken at the March- April, 1998 Therapeutics Committee Meeting- Rebecca Hockman, Pharm.D., BCPS, 
Monica Yost, Pharm.D., Patti Fatzinger, BS, Pharmacy Candidate, Dorothy McFadden, MA, R.D., CNSD, Clinical Nutrition 
pt/498.hi 
PLA VIX FOR PLATELET 
INHIBITION 
Clopidogrel (Plavix®- Sanofi I Bristol Myers 
Squibb Company), a new inhibitor of platelet 
aggregation, has recently been approved for 
formulary inclusion at L VH. Anti platelet 
agents have been proven to prevent the 
development and progression of thrombosis by 
inhibiting platelet activation and aggregation at 
sites of atherosclerosis. In comparison to other 
antiplatelet agents currently on formulary (ie. 
aspirin and ticlopidine), clopidogrel may possess 
superior efficacy, and has been associated with a 
higher safety profile. 
Clopidogrel is a selective ADP receptor 
antagonist, acting irreversibly through direct 
inhibition of ADP binding to its platelet 
receptor and of subsequent ADP-mediated 
activation of the glycoprotein llb/illa complex. 
Unlike aspirin, clopidogrel has no effect on 
cyclooxygenase or thrombin synthesis. 
Clopidogrel is currently indicated for the 
reduction of atherosclerotic events including 
myocardial infarction, stroke, and vascular death 
in patients with documented atherosclerosis. 
Clopidogrel undergoes first-pass metabolism in 
the liver to an unidentified active metabolite 
that is responsible for irreversibly modifying the 
ADP receptor on the platelet surface. Platelets 
exposed to clopidogrel are affected for their 
entire life span of 7 days. Platelet inhibition is 
observed within 2 hours of a single 75mg dose, 
and steady state is reached within 3-7 days 
following repeated 75mg doses. Following the 
last administration of clopidogrel, inhibition of 
platelet aggregation and prolongation of 
bleeding time return to baseline values within 5 
days. 
At high concentrations in vitro, clopidogrel 
inhibits cyp 450 (2C9) and may therefore 
interfere with the metabolism of phenytoin, 
tamoxifen, tolbutamide, torsemide, fluvastatin, J 
and many nonsteroidal anti-inflammatory drugs; 
however, there is no data to support the 
magnitude of these interactions. Co-
administration with warfarin, aspirin, and 
heparin has not been established and should be 
used with caution. 
The CAPRIE trial (the Clopidogrel versus 
Aspirin in Patients at Risk of Ischemic Events· 
trial) compared the use of Plavix® 75mg daily 
(n=9599) to aspirin 325mg daily (n-9586). The 
primary outcome of the study was the time to 
first occurrence of new ischemic stroke, new 
myocardial infarction, or other vascular death. 
Clopidogrel was associated with a lower 
incidence of outcome events of every kind and 
represented an overall risk reduction of 8.7%. 
The CAPRIE trial found the drug to be very 
well tolerated. Clopidogrel was found to have a 
safety profile similar to aspirin, but was 
associated with a lower incidence of 
gastrointestinal disturbances. Compared to 
ticlopidine, clopidogrel was associated with a 
much lower incidence of neutropenia and 
therefore does not require blood monitoring. 
Clopidogrel was associated with a higher 
incidence of diarrhea, pruritus, and purpura. 
With regard to benefit, side effects and cost, aspirin 
is still recommended as first line of therapy in the 
preventio~ of ischemic events. 
The recommended daily dose of Plavix~ is 75mg 
once daily with or without food. No dosage 
adjustment is necessary in elderly patients or in 
patients with renal impairment, but experience 
is limited in patients with severe hepatic disease. 
The drug was added to formulary with the intent 
that it be used as an alternative to ticlopidine in 
patients status post stroke. 
Dosage 
Aspirin 325mg daily 
Ticlopidine 250mg BID 
Clopidogrel75mg daily 




COUMADIN: WHAT ABOUT 
THE GENERIC? 
The FDA has recently approved the release of 
generic crystalline warfarin sodium products by 
manufacturers, Invamed and Barr Laboratories. 
Invamed has not marketed or released any 
information regarding their product; however, 
Barr's product is currently available. The generic 
products are receiving widespread attention 
regarding questions ofbioequivalence with DuPont 
Pharma's Coumadin®. 
The skepticism regarding generic warfarin is 
inevitable since historically generic warfarin 
products, such as Pan Warfarin®, have not been 
therapeutically successful. t.3 The narrow 
therapeutic index of warfarin, risk of adverse 
effects, numerous intra-and interpatient variables 
affecting drug response, and many drug 
interactions make bioeq¥ivalence and therapeutic 
equivalence especially concerning with 
Coumadin® and generic warfarin products.4 
According to the FDA, a generic product may be 
marketed if it meets the required bioequivalence 
guidelines for rate and extent of absorption of 80-
125% relative to the brand name product, and if it 
meets USP content uniformity standards. 1•3.S 
While these variables support bioequivalence, they 
may not assure therapeutic equivalence, especially 
with respect to medication with a narrow 
therapeutic index. In an attempt to improve the 
anticoagulant stability and reduce any potential 
overlap with the available dosage strengths, 
Dupont Pharma (makers of Coumadin®) has 
voluntarily chosen to employ guidelines which are 
approximately twice as stringent as those required 
by the USP. 6 Barr's product follows the standards 
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by the USP. 7 The differences in these production 
standards may raise questions about potential ( 
variations between brand and generic warfarin 
formulations. 
Questions about such variation are especially 
warranted with narrow therapeutic index 
medications and potentially harmful adverse 
effects. The most appropriate way to address these 
concerns is through clinical trials showing efficacy 
and safety by interchanging the brand with the 
generic products. In February, Barr released 
clinical trial data "proving" interchangeability 
between Coumadin® and their generic product8• 
This was a randomized, crossover study conducted 
to compare the efficacy and tolerability of Barr's 
warfarin sodium to Coumadin®. The study was 
performed in VA patients with atrial fibrillation, 
who were on stable doses of Coumadin® for at 
least six weeks before entering the study. Patients 
were randomized to receive either generic warfarin 
or brand Coumadin® for 21 days, and were then 
switched to the alternative for 21 days, and 
remained on that same agent for an additional21 ( 
days. 
The study enrolled fifty-five subjects randomized 
to treatment, but only 39 patients included in the 
primary analysis. No significant difference was 
demonstrated in averaged INR values between 
Coumadin® and Barr generic formulations during 
the crossover study. The authors reported no 
significant differences in adverse effects, with 
seven Barr product patients reporting at least one 
anticoagulation effect versus three Coumadin® 
brand patients reporting at least one 
anticoagulation effect. There was no mention of 
any of the adverse events requiring hospitalization, 
ER visits or unexpected office visits. The authors 
concluded that the "warfarin sodium preparations 
can be safely interchanged with no additional 
patient monitoring requirements as a result of the 
switch." 
Previous generic warfarin manufacturers have not 
attempted to support products with therapeutic ( 
equivalency trials. The Neutal and Smith tria18 ' 
intended to demonstrate efficacy and safety 
interchangeability between the Barr product and 
)umadin® product. The limitations of the study 
Jllclude: 1) a small sample size secondary to patient 
elimination and 2) the elimination of patients 
requiring a dosage adjustment makes extrapolation 
to the general population difficult. A larger patient 
population is needed to conclusively say that the 
products may be interchanged without need for 
additional laboratory monitoring. 
The average wholesale prices for a thirty day 
supply of the brand name drug, Coumadin®, 
ranges from $16.96 to $28.15 as compared to 
$15.26 to $25 .34 for Barr, s generic warfarin. 
Thus, the use of the generic product will represent 
a total savings in drug cost of about $2-$3 per 
month. The overall cost of warfarin therapy is also 
related to the cost of monitoring and treatment of 
bleeding episodes. It is still unknown if the 
differences in product manufacturing will result in 
more intra-subject INR variability. 
Until a larger study evaluates the inter-
( hangeability of the Coumadin® and Barr 
warfarin products, it is our recommendation that 
patients being managed effectively on Coumadin® 
not be switched to a different warfarin product. If 
a generic product is initiated on a ''warfarin naive 
patient" or interchanged for Coumadin® brand, 
there are still unanswered questions as to whether 
the production variations will result in wider drug 
content/tablet variation, and therefore fluctuations 
in INR measurements. In our judgement, a larger 
clinical trial is needed to conclusively verify 
therapeutic and safe interchangeability between 
Coumadin® and Barr Laboratories generic 
product, without the need for additional laboratory 
management. Many physicians are facing 
insurance plans or patient income requirements that 
are forcing change to generic therapy, despite the 
minimal difference in cost. If one must change to 
the generic formulation, we do not recommend the 
change without laboratory INR assessment. In our 
clinical judgement, an evaluation of the INR within 
5-7 days of the product interchange is necessary. 
Subsequent dosage changes based on INR 
monitoring, and monthly INR assessment should 
then continue in the same manner as that used with 
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the Coumadin® product. Please remember that 
another generic product by Invamed is scheduled 
for release, date unknown, and no information is 
available for bioequivalence or therapeutic 
equivalence for this product. If a generic product 
is prescribed, we recommend specifying Barr 
generic until more information is released for the 
Invamed product. 
Please call the clinical office Ext. #8884 for 
additional questions. 
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CEFEPIME FOR 
CEFTAZIDIME 
As reported in an earlier Medical Staff Progress 
News (February 1998), the Therapeutics 
Committee approved the formulary addition of 
cefepime (Maxipime~) in November 1997. This 
addition included the approval of an automatic 
substitution policy between ceftazidime and 
cefepime, that would occur when efficient 
laboratory testing was available to the 
Microbiology Department at L VH. Exceptions 
to the auto-substitution policy include the 




Ceftazidime will remain on formulary for these 
restricted patient populations. 
The Automatic Therapeutic Substitution Policy 
will begin on June 8, 1998. All orders written 
on Monday June 8, 1998 for the initiation of 
ceftazidime therapy will be substituted, without 
contact to the physician, with cefepime in the 
following manner: 
cefepime lgm Q12H will be substituted for 
ceftazidime lgm Q8H 
and 
cefepime 2gm Q 12H will be substituted for 
ceftazidime 2gm Q8H 
For patients requiring ceftazidime dosing 
regimens other than 1 or 2gm IV Q8H, the 
ordering physician will be contacted by the 
inpatient pharmacists to discuss equivalent 
cefepime dosing regimens. Patients already on 
ceftazidime on the date of automatic substitution, 
will continue on ceftazidime therapy. For any 
indications where physicians wish to use 
ceftazidime over cefepime, the physician should 
include on the written order for ceftazidime, a 
statement of "DO NOT SUBSTITUTE." The 
automatic substitution will occur for all 
ceftazidime orders EXCEPT those marked "Do 
Not Substitute" by the physician, or for therapy 
in pediatrics, neutropenic fever, and meningitis 
patient populations. Please contact the pharmacy 
at #8886 o;r #8884 with questions. 
NUTRITION 
SUBCOMMITTEE UPDATE 
The nutrition subcommittee met to review the 
composition of the enteral formulary and to 
determine the most appropriate and cost effective 
enteral formulas. Specialty formulas, such as 
Impact with Fiber, Glucerna, Peptamen VHP and 
Vivonex Plus are substantially more expensive 
than standard enteral formulas and should not be 
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used routinely . Justification for use of higher 
cost specialty products has traditio~lly been that ( 
use of these products reduces length of stay or 
complications. Articles published by Richard 
Barton, MD and Jeffery Saffle MD were 
reviewed concerning the effectiveness of 
immune-enhancing formulas. As per discussion, 
it was decided that immune enhancing formulas 
are only effective for certain patient populations, 
and should not be used exclusively in the trauma 
and burn population. Reducing the use of Impact 
with Fiber by half will save the hospital $25,000 
annually. Criteria are being developed for use of 
specialty formulas to identify those patient 
populations where these products are beneficial. 
Some initial changes that were approved by the 
subcommittee and presented to Therapeutics 
Committee: 
Change 
Replacement of Resource Fruit 
Beverage with Nutrashake Citrus 
as po supplement for clear liquid diets 
Benefit 
Cost Savings: $3020 
Replacement of Ensure pudding 
with Resource Nutritious Pudding 
Cost savings: $1300 
Replacement of Vivonex Peds with 
Peptamen Jr for malabsorption, altered 
GI function and food allergies Cost savings: $175 
Improved continuity with outpt 
Less waste and contamination 
The Food and Nutrition Services department is 
working with Supplier Services to obtain 
competitive bidding for the enteral formulary 
products. Muhlenberg Hospital Center will also 
be included in the contract negotiations for 
pricing of these products. The Nutrition 
Subcommittee will continue to meet to develop 
guidelines for the use of specialty products. 
Please review the attached list of enteral 
formulary products and the cost for each product. 
Keep in mind the appropriate use of each product 




COSTS OF ENTERAL PRODUCTS Page 15 
Standard 
1. Osmolite Isotonic $ .58/can 
( 
Non fiber containing $ 2.32/liter 
Standard 1 callcc 
2. Jevity Isotonic $ .92/can 
Fiber con~ining $3.68/liter 
Standard 1 'cal/cc w/fiber 
3. Two Cal Nutrient dense $ .91/can 
Non fiber containing 2 cal/cc $ 3.64/liter 
For fluid restricted patients 
4. Promote w/fiber High Protein $ .92/can 
1cal/cc Fiber containing $ 3. 68/liter 
Indicated for trauma, burns 
high protein needs 
Specialized 
5. Glucerna Reduced carbohydrate $ 1.76/can 
1 cal/cc, Fiber containing $ 7. 02/liter 
For uncontrolled diabetes 
after trial of Jevity 
6. Nepro Moderate Protein, low K $ 2.43/can 
2 cal/cc $9.72/liter 
For dialysis patients 
7. Impact w/fiber Immune enhancing $ 6.17/can 
( 1 cal/cc, fiber containing. $24.68/liter 
For sepsis, abdominal 
trauma, TBSA > 40% 
8. PeptamenVHP Semi elemental, 1 cal/cc $ 5.00/can 
For use with prolonged NPO $20 .00/liter 
hypoalbuminemia, protein 
losing enteropathy 
9. Vivonex Plus Elemental, minimal fat, 1 cal/cc $ 4.92/packet 
Pancreatitis, IBD, fistulas $ 16.40/ mixed liter* 
SBS, gut atrophy, radiation *includes labor for mixing 
enteritis 
10. Renal cal Low Protein, electrolyte free $5.97/can 
2 cal/cc $23.88/liter 
For renal failure without dialysis 
11. Nutrihep Low protein, high BCAA $12.26/can 
1.5 callcc $29.04niter 
For encephalopathy 
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TEMPLATE BLEEDING TIME 
DAVID PRAGER, M.D. 
MEDICAL DIRECTOR 
HEMATOLOGY AND COAGULATION LABS 
THE TEMPLATE BLEEDING TIME (TBT)- WHAT IS ACCOMPLISHED? 
( 
The template bleeding time was first described in 1901 by Milian (1) and subsequently ( 
modified by Duke (2) and Mielke (3). Besides leaving a permanent scar, the TBT is not a 
useful test to predict a patient's propensity to bleed excessively during or after a surgical 
procedure. The following are some facts based upon the medical literature concerning the 
TBT. 
Cardiac surgery 
A. There is no correlation between the TBT and either a decrease in the hemoglobin level 
or the amount of chest tube drainage in a prospective study of 43 patients undergoing 
cardiopulmonary bypass. (4) 
B. 9 of 65 patients undergoing cardiac surgery had excessive bleeding, but their mean 
TBT's did not differ from those of the remainder, who did not bleed excessively. (5) 
C. In a retrospective study of 92 patients undergoing cardiopulmonary bypass, 14 patients 
had prolonged TBT's. Those patients did not receive greater amounts of blood products 
than did patients with normal TBT's. (6) 
D. No significant correlation between chest tube drainage or the number of red cells 
transfused and the TBT. (7) 
( 
( 
Template Bleeding Time 
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Non-cardiac surgery 
A. In patients undergoing hip surgery with prolonged TBT, there was no excessive 
bleeding. (8) 
B. Retrospective review of 1 ,941 general surgery patients and 11 0 patients had a prolonged 
TBT. There was no correlation between the TBT and bleeding. (9) 
C. 101 patients underwent preoperative TBT screening prior to thyroid and abdominal 
surgery. Preoperative TBT was not felt to be helpful in predicting surgical bleeding. 
(10) 
D. 52 consecutive patients underwent emergency or unplanned operations. In patients with 
prolonged TBT' s , there was no increased intraoperative bleeding compared to patients 
with normal TBT's. (11) 
E. In 282 general and vascular surgery patients who had normal and abnormal TBT's, 
there was no excessive bleeding in patients with abnormal TBT' s compared to patients 
with normal TBT's. (12) 
Summary Statements by Various Authors 
1. There is no medical literature evidence that a prolonged TBT predicts which patients 
will experience excessive surgical bleeding. (13) 
2. There is little reason to perform the TBT for screening purposes outside the confmes of 
a study. (13) 
3. The use of the TBT as a routine screening test is not warranted at the present time. (13) 
4. No evidence exists that the TBT is indeed a predictor of surgical blood losses during or 
after surgical operations and that no evidence exists that efforts in standardizations have 
resulted in any significant enhancement in the utility of the test.(14) 
5. Based on our results, we suggest not using the TBT in the preoperative screening of 
patients undergoing coronary surgery without a history of bleeding. (14). 
6. The TBT is often an unreliable measure of platelet function. (15) 
7. Preoperative TBT is not warranted simply because the patient is taking an "anti-platelet 
drug" (13) 
8. Relatively few of the "anti-platelet" drugs that affect platelet aggregation in vitro 
prolong the TBT (13). 
Suggestions 
1. Do not order a TBT for use as a predictor of intra-operative or postoperative bleeding. 
2. Do not order serial TBT's for any reason. 
3. Do not order a TBT in order to determine why a postoperative patient is bleeding. 
4. Do not order a TBT in a patient with thrombocytopenia (platelets less than 
100,000/mm.3). 
5. There is not a single test available that will accurately evaluate all aspects of platelet 
function. 
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